Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) and Medicure (OTCMKTS:MCUJF – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.
Earnings and Valuation
This table compares Achieve Life Sciences and Medicure”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Achieve Life Sciences | N/A | N/A | -$54.65 million | ($1.12) | -5.13 |
| Medicure | $20.65 million | 0.40 | -$5.08 million | ($0.47) | -1.70 |
Insider & Institutional Ownership
33.5% of Achieve Life Sciences shares are held by institutional investors. 3.0% of Achieve Life Sciences shares are held by company insiders. Comparatively, 12.9% of Medicure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Achieve Life Sciences and Medicure’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Achieve Life Sciences | N/A | -193.49% | -111.88% |
| Medicure | -21.65% | -44.34% | -26.22% |
Analyst Recommendations
This is a summary of current recommendations and price targets for Achieve Life Sciences and Medicure, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Achieve Life Sciences | 1 | 0 | 3 | 2 | 3.00 |
| Medicure | 0 | 0 | 0 | 0 | 0.00 |
Achieve Life Sciences presently has a consensus target price of $14.67, suggesting a potential upside of 155.07%. Given Achieve Life Sciences’ stronger consensus rating and higher probable upside, research analysts clearly believe Achieve Life Sciences is more favorable than Medicure.
Risk & Volatility
Achieve Life Sciences has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500. Comparatively, Medicure has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.
About Achieve Life Sciences
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
About Medicure
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
